| Literature DB >> 31100122 |
Markella V Zanni1, Magid Awadalla2, Mabel Toribio1, Jake Robinson3, Lauren A Stone1, Diana Cagliero1, Adam Rokicki2, Connor P Mulligan2, Jennifer E Ho4, Anne M Neilan5,6, Mark J Siedner6, Virginia A Triant6,7, Takara L Stanley1, Lidia S Szczepaniak8, Michael Jerosch-Herold9, Michael D Nelson10, Tricia H Burdo3, Tomas G Neilan2.
Abstract
Human immunodeficiency virus (HIV) imparts increased heart failure risk to women. Among women with HIV (WHIV), immune pathways relating to heart failure precursors may intimate targets for heart failure prevention strategies. Twenty asymptomatic, antiretroviral-treated WHIV and 14 non-HIV-infected women matched on age and body mass index underwent cardiac magnetic resonance imaging and immune phenotyping. WHIV (vs non-HIV-infected women) exhibited increased myocardial fibrosis (extracellular volume fraction, 0.34 ± 0.06 vs 0.29 ± 0.04; P = .002), reduced diastolic function (diastolic strain rate, 1.10 ± 0.23 s-1 vs 1.39 ± 0.27 s-1; P = .003), and heightened systemic monocyte activation. Among WHIV, soluble CD163 levels correlated with myocardial fibrosis (r = 0.53; P = .02), while circulating inflammatory CD14+CD16+ monocyte CCR2 expression related directly to myocardial fibrosis (r = 0.48; P = .04) and inversely to diastolic function (r = -0.49; P = .03). Clinical Trials Registration. NCT02874703.Entities:
Keywords: HIV; diastolic dysfunction; inflammation; myocardial fibrosis; women
Mesh:
Substances:
Year: 2020 PMID: 31100122 PMCID: PMC7325805 DOI: 10.1093/infdis/jiz184
Source DB: PubMed Journal: J Infect Dis ISSN: 0022-1899 Impact factor: 5.226